SG Americas Securities LLC Purchases 35,982 Shares of Solventum Corporation $SOLV

SG Americas Securities LLC boosted its holdings in shares of Solventum Corporation (NYSE:SOLV) by 38.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 129,663 shares of the company’s stock after buying an additional 35,982 shares during the period. SG Americas Securities LLC’s holdings in Solventum were worth $8,467,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Strong Tower Advisory Services increased its holdings in Solventum by 4.9% in the 1st quarter. Strong Tower Advisory Services now owns 112,703 shares of the company’s stock valued at $7,360,000 after buying an additional 5,295 shares during the period. Hsbc Holdings PLC lifted its holdings in shares of Solventum by 2.3% during the 4th quarter. Hsbc Holdings PLC now owns 227,139 shares of the company’s stock worth $18,021,000 after acquiring an additional 5,015 shares during the period. Rockefeller Capital Management L.P. boosted its position in shares of Solventum by 15.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 6,450 shares of the company’s stock valued at $511,000 after acquiring an additional 864 shares in the last quarter. Corient Private Wealth LLC boosted its position in shares of Solventum by 18.5% during the 4th quarter. Corient Private Wealth LLC now owns 49,092 shares of the company’s stock valued at $3,859,000 after acquiring an additional 7,653 shares in the last quarter. Finally, Bayban acquired a new stake in shares of Solventum during the 4th quarter valued at about $134,000.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on SOLV. Rothschild & Co Redburn assumed coverage on shares of Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target for the company. Weiss Ratings downgraded Solventum from a “hold (c+)” rating to a “hold (c)” rating in a report on Friday. KeyCorp upped their price objective on Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Wedbush started coverage on Solventum in a report on Friday, May 15th. They issued an “outperform” rating and a $94.00 target price for the company. Finally, UBS Group downgraded Solventum from a “buy” rating to a “neutral” rating and set a $50.00 target price for the company. in a research report on Thursday, May 14th. Eight investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $84.25.

Solventum Stock Performance

Shares of NYSE:SOLV opened at $79.56 on Friday. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20. The firm has a market cap of $13.78 billion, a PE ratio of 9.75, a price-to-earnings-growth ratio of 1.23 and a beta of 0.69. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The business has a fifty day moving average of $74.58 and a 200-day moving average of $74.62.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm’s revenue for the quarter was down 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities research analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.